These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 17827012)

  • 1. The design and preliminary structure-activity relationship studies of benzotriazines as potent inhibitors of Abl and Abl-T315I enzymes.
    Cao J; Fine R; Gritzen C; Hood J; Kang X; Klebansky B; Lohse D; Mak CC; McPherson A; Noronha G; Palanki MS; Pathak VP; Renick J; Soll R; Zeng B; Zhu H
    Bioorg Med Chem Lett; 2007 Nov; 17(21):5812-8. PubMed ID: 17827012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flying under the radar: the new wave of BCR-ABL inhibitors.
    Quintás-Cardama A; Kantarjian H; Cortes J
    Nat Rev Drug Discov; 2007 Oct; 6(10):834-48. PubMed ID: 17853901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based design and synthesis of novel macrocyclic pyrazolo[1,5-a] [1,3,5]triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities.
    Nie Z; Perretta C; Erickson P; Margosiak S; Lu J; Averill A; Almassy R; Chu S
    Bioorg Med Chem Lett; 2008 Jan; 18(2):619-23. PubMed ID: 18055206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, structure-activity relationship, and p210(bcr-abl) protein tyrosine kinase activity of novel AG 957 analogs.
    Kaur G; Narayanan VL; Risbood PA; Hollingshead MG; Stinson SF; Varma RK; Sausville EA
    Bioorg Med Chem; 2005 Mar; 13(5):1749-61. PubMed ID: 15698792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyrrolo[1,2-f]triazines as JAK2 inhibitors: achieving potency and selectivity for JAK2 over JAK3.
    Harikrishnan LS; Kamau MG; Wan H; Inghrim JA; Zimmermann K; Sang X; Mastalerz HA; Johnson WL; Zhang G; Lombardo LJ; Poss MA; Trainor GL; Tokarski JS; Lorenzi MV; You D; Gottardis MM; Baldwin KF; Lippy J; Nirschl DS; Qiu R; Miller AV; Khan J; Sack JS; Purandare AV
    Bioorg Med Chem Lett; 2011 Mar; 21(5):1425-8. PubMed ID: 21282055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, structural analysis, and SAR studies of triazine derivatives as potent, selective Tie-2 inhibitors.
    Hodous BL; Geuns-Meyer SD; Hughes PE; Albrecht BK; Bellon S; Caenepeel S; Cee VJ; Chaffee SC; Emery M; Fretland J; Gallant P; Gu Y; Johnson RE; Kim JL; Long AM; Morrison M; Olivieri PR; Patel VF; Polverino A; Rose P; Wang L; Zhao H
    Bioorg Med Chem Lett; 2007 May; 17(10):2886-9. PubMed ID: 17350837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and SAR of 4-(3-hydroxyphenylamino)pyrrolo[2,1-f][1,2,4]triazine based VEGFR-2 kinase inhibitors.
    Borzilleri RM; Cai ZW; Ellis C; Fargnoli J; Fura A; Gerhardt T; Goyal B; Hunt JT; Mortillo S; Qian L; Tokarski J; Vyas V; Wautlet B; Zheng X; Bhide RS
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1429-33. PubMed ID: 15713401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl.
    Eck MJ; Manley PW
    Curr Opin Cell Biol; 2009 Apr; 21(2):288-95. PubMed ID: 19217274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and preliminary structure-activity relationship studies of novel benzotriazine based compounds as Src inhibitors.
    Noronha G; Barrett K; Cao J; Dneprovskaia E; Fine R; Gong X; Gritzen C; Hood J; Kang X; Klebansky B; Li G; Liao W; Lohse D; Mak CC; McPherson A; Palanki MS; Pathak VP; Renick J; Soll R; Splittgerber U; Wrasidlo W; Zeng B; Zhao N; Zhou Y
    Bioorg Med Chem Lett; 2006 Nov; 16(21):5546-50. PubMed ID: 16931012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.
    Mahboobi S; Dove S; Sellmer A; Winkler M; Eichhorn E; Pongratz H; Ciossek T; Baer T; Maier T; Beckers T
    J Med Chem; 2009 Apr; 52(8):2265-79. PubMed ID: 19301902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-dimensional quantitative structure-activity relationship studies on novel series of benzotriazine based compounds acting as Src inhibitors using CoMFA and CoMSIA.
    Gueto C; Ruiz JL; Torres JE; Méndez J; Vivas-Reyes R
    Bioorg Med Chem; 2008 Mar; 16(5):2439-47. PubMed ID: 18065233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and SAR of new pyrrolo[2,1-f][1,2,4]triazines as potent p38 alpha MAP kinase inhibitors.
    Wrobleski ST; Lin S; Hynes J; Wu H; Pitt S; Shen DR; Zhang R; Gillooly KM; Shuster DJ; McIntyre KW; Doweyko AM; Kish KF; Tredup JA; Duke GJ; Sack JS; McKinnon M; Dodd J; Barrish JC; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2739-44. PubMed ID: 18364256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, inhibitory activity, and SAR studies of hydrophobic p-aminosalicylic acid derivatives as neuraminidase inhibitors.
    Zhang J; Wang Q; Fang H; Xu W; Liu A; Du G
    Bioorg Med Chem; 2008 Apr; 16(7):3839-47. PubMed ID: 18304821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological evaluation of pyrrolopyridazine derivatives as novel HER-2 tyrosine kinase inhibitors.
    Tang PC; Feng J; Huang L; Xu Z; Cheng L; Zhang X; Zhang L; Hu B
    Bioorg Med Chem Lett; 2009 Nov; 19(22):6437-40. PubMed ID: 19815412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of 4-[(s-triazin-2-ylamino)methyl]-N-(2-aminophenyl)-benzamides and their analogues as a novel class of histone deacetylase inhibitors.
    Paquin I; Raeppel S; Leit S; Gaudette F; Zhou N; Moradei O; Saavedra O; Bernstein N; Raeppel F; Bouchain G; Fréchette S; Woo SH; Vaisburg A; Fournel M; Kalita A; Robert MF; Lu A; Trachy-Bourget MC; Yan PT; Liu J; Rahil J; MacLeod AR; Besterman JM; Li Z; Delorme D
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1067-71. PubMed ID: 18160287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-guided discovery of cyclin-dependent kinase inhibitors.
    Fischmann TO; Hruza A; Duca JS; Ramanathan L; Mayhood T; Windsor WT; Le HV; Guzi TJ; Dwyer MP; Paruch K; Doll RJ; Lees E; Parry D; Seghezzi W; Madison V
    Biopolymers; 2008 May; 89(5):372-9. PubMed ID: 17937404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
    Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of potent and selective azaindole-based Rho kinase (ROCK) inhibitors.
    Schirok H; Kast R; Figueroa-Pérez S; Bennabi S; Gnoth MJ; Feurer A; Heckroth H; Thutewohl M; Paulsen H; Knorr A; Hütter J; Lobell M; Münter K; Geiss V; Ehmke H; Lang D; Radtke M; Mittendorf J; Stasch JP
    ChemMedChem; 2008 Dec; 3(12):1893-904. PubMed ID: 18973168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.
    Santucci MA; Corradi V; Mancini M; Manetti F; Radi M; Schenone S; Botta M
    ChemMedChem; 2009 Jan; 4(1):118-26. PubMed ID: 19039816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.